-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Ascentage Pharma Highlights Dual-Engine Growth And Global Pipeline Expansion During J.P. Morgan Healthcare Conference Presentation

Benzinga·01/15/2026 06:54:32
Listen to the news
  • Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presence
  • Next-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipeline
  • Multiple global registrational Phase III trials are progressing rapidly